Off-Target Binding of Miglustat to Glycogen Debranching Enzyme.

Drew Barber, Neha Mishra, Fiona Hegarty, Aviv Paz

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Drew BarberHauptman-Woodward Research Institute, University at Buffalo, The State University of New York, Buffalo, NY 14203, USA.

Neha MishraHauptman-Woodward Research Institute, University at Buffalo, The State University of New York, Buffalo, NY 14203, USA.ORCID 0000-0002-5436-7946

Fiona HegartySmith College, Northampton, MA 01063, USA.

Aviv PazHauptman-Woodward Research Institute, University at Buffalo, The State University of New York, Buffalo, NY 14203, USA.ORCID 0000-0003-0792-492X

Funding

NIH HHS 1R01GM149871-24U.S. National Science Foundation 1231306

6 · The paper itself

Abstract

The iminosugar N-butyldeoxynojirimycin (Miglustat) is clinically used for the inhibition of ceramide glucosyltransferase for treating Type 1 Gaucher and Niemann-Pick type C diseases. This drug also inhibits glycogen debranching enzyme (GDE), the enzyme responsible for terminal glycogen catabolism via coordinated glucotransferase and amylo-α-1,6-glucosidase (GC) activities, although the structural basis for inhibition has been undefined. Here, we report the crystal structure of

Indexed as

1-DeoxynojirimycinEnzyme InhibitorsGlycogen Debranching Enzyme SystemBinding SitesCrystallography, X-RayGlucosyltransferasesHumansModels, MolecularMolecular Docking SimulationProtein Binding1-DeoxynojirimycinEnzyme InhibitorsGlucosyltransferasesGlycogen Debranching Enzyme Systemmiglustatamylo-α-1,6-glucosidaseGDEglycogen debranching enzymeglycogen metabolismiminosugarsMiglustatN-butyldeoxynojirimycin

Identifiers

PMID42353206

DOI10.3390/ijms27125490

PMCPMC13299489

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.